Tissot E, Woronoff-Lemsi M C
CHU Besançon, Boulevard Fleming, 25030 Besançon.
Rev Neurol (Paris). 2001 Sep;157(8-9 Pt 2):1169-74.
Economic assessments for multiple sclerosis (MS) first appeared in the nineties. Drug costs were initially marginal before the recent introduction of interferon-beta. To evaluate the burden of MS, economic studies were carried out in addition to specific cost-of-illness studies. Like other chronic illnesses, MS patients can have mild to moderate or severe disabilities. This led to the need for indirect cost analysis. We interrogated the Medline database from 1985 to 2001 to select cost-of-illness studies. We present our findings here by type of methodology used, health care system and level of disability. We found that indirect costs are related to patient age at symptom onset (20-40 years). In most counties, excepting the United Kingdom, hospital costs dominate direct costs. Finally, MS costs are related to the stage of the disease.
多发性硬化症（MS）的经济评估最早出现在20世纪90年代。在近期引入β-干扰素之前，药物成本起初微不足道。为评估MS的负担，除了特定的疾病成本研究外，还开展了经济研究。与其他慢性疾病一样，MS患者可能有轻度至中度或重度残疾。这导致了间接成本分析的必要性。我们检索了1985年至2001年的Medline数据库以选择疾病成本研究。我们在此按所用方法类型、医疗保健系统和残疾程度展示我们的研究结果。我们发现间接成本与症状出现时的患者年龄（20 - 40岁）相关。在大多数国家，除了英国，医院成本在直接成本中占主导。最后，MS成本与疾病阶段相关。
